---
title: "Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/211446916.md"
description: "Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results"
datetime: "2024-08-13T11:40:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/211446916.md)
  - [en](https://longbridge.com/en/news/211446916.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/211446916.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/211446916.md) | [English](https://longbridge.com/en/news/211446916.md)


# Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

CAMBRIDGE, Mass., Aug. 13, 2024 ( GLOBE NEWSWIRE ) -- Mersana Therapeutics, Inc. ( NASDAQ: MRSN ) , a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ( ADCs ) targeting cancers in areas of high unmet medical need, today ...

### 相關股票

- [Mersana Therap (MRSN.US)](https://longbridge.com/zh-HK/quote/MRSN.US.md)

## 相關資訊與研究

- [Kepler Capital  Reaffirms Their Buy Rating on MERSEN (0Q6Q)](https://longbridge.com/zh-HK/news/280552049.md)
- [Day One concludes Mersana Therapeutics acquisition](https://longbridge.com/zh-HK/news/271914141.md)
- [Mersana Therapeutics Announces Board and Management Changes Following Merger](https://longbridge.com/zh-HK/news/271666055.md)
- [Mersana Therapeutics Terminates Sales Agreement With Cowen and Company](https://longbridge.com/zh-HK/news/271666065.md)
- [Mersana Therapeutics Faces High Stakes with Potential Day One Biopharmaceuticals Merger Delays](https://longbridge.com/zh-HK/news/266012188.md)